Stockwatch: Burying products that fade to black
This article was originally published in Scrip
There is a little-recognised category of development pharmaceutical products that seem to hang around for years, having very slow progress through clinical trials and then one day, they quietly disappear all together from the company’s pipeline. One renowned London-based fund manager used to honor the practice with the phrase “pharma buries its dead at night”. This used to be quite true up to about 2003, but the rise of the patent cliff has brought greater scrutiny to pharmaceutical companies’ pipelines.
You may also be interested in...
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
Following Mylan’s first-quarter 2020 earnings announcement, all the biggest generic pharmaceutical companies have now reported. Concerns about supply chain disruptions in March have proven to have been overblown and guidance has largely been reaffirmed. So, are generics immune from coronavirus?
As the first-quarter 2020 earnings season transitions from big pharma to the long tail of smaller biotech companies, the coronavirus pandemic-related dynamics of channel stocking and greatly diminished numbers of clinic visits have magnified effects at companies with single underperforming drugs.